Dentsply Sirona Lowers 2026 Guidance Amid Weak Equipment Demand
Dentsply Sirona (XRAY) has lowered its full-year 2026 financial guidance following a third-quarter earnings report that revealed a 7.6% decline in reported revenue. The company reduced its net sales expectations to approximately $3.5 billion and cut its adjusted earnings per share (EPS) guidance to a range of $1.20–$1.30, down from the previous estimate of $1.40–$1.50. Despite these headwinds caused by weak dental equipment demand and rising distribution costs, the company is aggressively investing in long-term growth strategies. This includes a sixfold increase in clinical education spending in North America to drive product adoption and continued expansion within its Wellspect Healthcare division, which saw 10% revenue growth. Management remains focused on debt reduction and stabilizing core equipment sales to improve financial flexibility.

Tickers: $XRAY
Topics: dental equipment earnings report financial results revenue guidance